^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Mesothelioma

    Related cancers:
    6d
    A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers (clinicaltrials.gov)
    P1, N=180, Recruiting, Novartis Pharmaceuticals | Trial completion date: Feb 2026 --> Sep 2027 | Trial primary completion date: Feb 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • KFA115
    6d
    A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=61, Terminated, Takeda | Recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Jan 2025 | N=313 --> 61 | Trial completion date: Aug 2026 --> Jan 2025; Clinical Futility of TAK 500 met. No further development with this compound
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Keytruda (pembrolizumab) • TAK-500
    7d
    Rare Metastatic Mesothelioma Occupying Intra-Atrial Cavity, Released by an Emergency Surgery: A Case Report and Literature Review. (PubMed, Surg Case Rep)
    Surgical removal of intracardiac tumors that cause circulatory and respiratory instability is essential for the prevention of sudden death, regardless of prognostic determinants. This case demonstrates that mesotheliomas can metastasize to the endocardium. Even when nuclear atypia and negative results for immunohistochemical tests for the three mesothelioma markers suggest carcinoma, mesothelioma should still be considered and p16/CDKN2A co-deletion should be evaluated.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • WT1 (WT1 Transcription Factor)
    |
    CDKN2A deletion
    8d
    NuTide:303: NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=91, Recruiting, NuCana plc | Trial completion date: Jan 2025 --> Dec 2025 | Trial primary completion date: Jan 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    Keytruda (pembrolizumab) • docetaxel • fosifloxuridine nafalbenamide (NUC-3373) • levoleucovorin calcium
    9d
    Is ADC a rising star in solid tumor? An umbrella review of systematic reviews and meta-analyses. (PubMed, BMC Cancer)
    Based on the available evidence, in breast cancer, ADCs were proved to with significant improvements in prolonging survival time and demonstrates a tolerable safety profile. Meanwhile, ADCs were proved to have enormous potential for the treatment of solid tumors. However, well-designed, multi-center RCTs need to further identify its potential in various solid tumors.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR positive
    |
    Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    11d
    Diagnostic trap: a case report of intimal sarcoma occurring in the left atrium. (PubMed, Front Cardiovasc Med)
    Adjuvant chemotherapy and radiotherapy are suggested. In advanced cases, comprehensive immunotherapy methods may be employed to enhance patient survival rates and quality of life.
    Journal • IO biomarker
    |
    MDM2 (E3 ubiquitin protein ligase) • ERG (ETS Transcription Factor ERG) • VIM (Vimentin)
    11d
    FABP5 is a key player in metabolic modulation and NF-κB dependent inflammation driving pleural mesothelioma. (PubMed, Commun Biol)
    Our findings unveil a reciprocal relationship between lipid metabolism and inflammation in PM, providing a foundation for targeted therapeutic strategies. Overall, this comprehensive investigation offers insights into the intricate molecular mechanisms driving PM pathogenesis and identifies potential avenues for therapeutic intervention.
    Journal
    |
    FABP5 (Fatty Acid Binding Protein 5)
    12d
    APG-2449 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=150, Recruiting, Ascentage Pharma Group Inc. | Trial completion date: Feb 2025 --> Jan 2028 | Trial primary completion date: Jan 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK positive • ROS1 fusion • ROS1 positive
    |
    APG-2449
    14d
    Leveraging Immunogenic Cell Death to Enhance the Immune Response against Malignant Pleural Mesothelioma Tumors. (PubMed, J Am Chem Soc)
    In contrast, complex 1C, characterized by high phagocytosis rates and high necrosis rates, failed to elicit a sustained immune response upon following vaccination; however, it triggered selective activation of calreticulin in tumors upon direct in vivo administration. Overall, this study offers a framework for predicting ICD effects in vivo for structurally similar Au(III) complexes, with the potential for extension to other series of metal complexes.
    Journal
    |
    CALR (Calreticulin)
    15d
    Stereotactic Body Radiation Therapy with Immunotherapy for the Treatment of Mesothelioma (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Mayo Clinic | Trial primary completion date: May 2025 --> May 2026
    Trial primary completion date • IO biomarker
    17d
    miRNA-503 inhibition exerts anticancer effects and reduces tumor growth in mesothelioma. (PubMed, J Exp Clin Cancer Res)
    Our study is the first reporting an oncomiR role for miR-503 in MM and suggests that its inactivation could have a clinical value in MM patients. This study reveals that miRNA-503 acts as an oncomiR in MM suggesting that its inhibition, through LNP delivery, has the potential to be considered as a novel therapeutic strategy in MM.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • SPP1 (Secreted Phosphoprotein 1) • TIMP2 (TIMP Metallopeptidase Inhibitor 2) • SERPINE1 (Serpin Family E Member 1) • MIR503 (MicroRNA 503) • S1PR1 (Sphingosine-1-Phosphate Receptor 1) • CCNG1 (Cyclin G1)
    |
    cisplatin
    17d
    M2-like tumor-associated macrophages may promote tumor progression in malignant pleural mesothelioma. (PubMed, Transl Oncol)
    During MPM progression, M2-like TAMs may induce tumor cell proliferation and aggressiveness, contributing to the poor prognosis in MPM patients.
    Journal
    |
    CD163 (CD163 Molecule) • CRP (C-reactive protein)
    17d
    Telomeres and telomerase in mesothelioma: Pathophysiology, biomarkers and emerging therapeutic strategies (Review). (PubMed, Int J Oncol)
    Research reveals the promise of the various approaches therapeutically targeting telomerase, with favorable results in pre‑clinical models and inconclusive findings in clinical trials. The present review examines the role of telomere biology in MM and its implications in diagnosis, prognosis, and therapy.
    Review • Journal
    |
    TERT (Telomerase Reverse Transcriptase)
    18d
    A Study of SGN-MesoC2 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=365, Recruiting, Seagen Inc. | Trial completion date: Nov 2028 --> Feb 2029 | Trial primary completion date: Nov 2028 --> Feb 2028
    Trial completion date • Trial primary completion date
    18d
    Bi-MAPS: Evaluating Ivonescimab As a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy (clinicaltrials.gov)
    P2, N=38, Not yet recruiting, Intergroupe Francophone de Cancerologie Thoracique
    New P2 trial
    |
    Yidafan (ivonescimab)
    18d
    A study of EnGeneIC Dream Vectors (EDV's) packaged with the chemotherapy, E-EDV-D682 given simultaneously as non-targeted EDVs carrying an immune enhancer called EDV-GC, in participants with advanced epidermal growth factor expressing cancers whose disease has progressed after one or two treatment regimes, or where other standard therapies are not appropriate. (EGFR EDV-D682/GC Trial) (ACTRN12625000203459)
    P1/2, N=160, Not yet recruiting, EnGeneIC Pty Limited
    New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression • EGFR positive
    18d
    Imaging biomarkers of response to immunotherapy in patients with malignant mesothelioma (ACTRN12623000632695)
    P=N/A, N=40, Recruiting, The University of Western Australia | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    18d
    The phenogenomic landscapes of pleural mesothelioma tumor microenvironment predict clinical outcomes. (PubMed, J Transl Med)
    Our findings underscore the intricate interplay between the tumor genome, TME composition, and clinical outcomes in MPM. These data support the potential of integrating genomic and TME profiling to develop more precise patient stratification strategies and potentially optimize therapeutic approaches, including immunotherapy.
    Clinical data • Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD4 (CD4 Molecule)
    19d
    CD276 as a critical independent biomarker and immune checkpoint inhibitor target in epithelioid mesothelioma-TCGA study. (PubMed, J Thorac Dis)
    It is associated with the glycolytic pathway and may contribute to ATP generation in epithelioid mesothelioma. CD276 inhibitors might contribute to better prognosis in patients with epithelioid mesothelioma.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CD276 (CD276 Molecule) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PKM (Pyruvate Kinase M1/2)
    19d
    Short Neoadjuvant Hemithoracic IMRT for MPM (clinicaltrials.gov)
    P1/2, N=100, Active, not recruiting, University Health Network, Toronto | Trial completion date: Sep 2024 --> Sep 2027 | Trial primary completion date: Sep 2024 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin
    19d
    TOAST IT: Heated Intra-peritoneal Chemotherapy with Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients (clinicaltrials.gov)
    P1, N=2, Terminated, Mayo Clinic | Trial completion date: Jan 2025 --> Oct 2024 | Active, not recruiting --> Terminated; slow accrual
    Trial completion date • Trial termination
    |
    cisplatin • doxorubicin hydrochloride • daunorubicin
    19d
    Tumour-wide RNA splicing aberrations generate actionable public neoantigens. (PubMed, Nature)
    Moreover, our study highlights a role for dysregulated splicing factor expression in specific cancer types, leading to recurrent patterns of neojunction upregulation. These findings establish a molecular basis for T cell-based immunotherapies addressing the challenges of intratumoural heterogeneity.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • GNAS (GNAS Complex Locus) • RPL22 (Ribosomal Protein L22)
    20d
    NR4A3 rearranged mesothelial tumour with evidence of infiltration after a 2-year follow up period: best regarded as NR4A3 rearranged low grade mesothelioma. (PubMed, Pathology)
    No abstract available
    Journal
    |
    NR4A3 (Nuclear receptor subfamily 4 group A member 3)
    21d
    SGNBB228-001: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors (clinicaltrials.gov)
    P1, N=275, Recruiting, Seagen Inc. | Trial completion date: Nov 2027 --> Apr 2028 | Trial primary completion date: Nov 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    PF-08046049
    22d
    Potential utility of miRNAs derived from pleural fluid extracellular vesicles to differentiate between benign and malignant pleural effusions. (PubMed, Transl Lung Cancer Res)
    PFEV miRNAs represent a novel bioresource with potential to aid in the diagnosis of pleural effusions. Larger prospective studies are needed to confirm their diagnostic utility.
    Journal • Pleural effusion
    |
    MIR200C (MicroRNA 200c) • MIR1246 (MicroRNA 1246) • MIR141 (MicroRNA 141) • MIR136 (MicroRNA 136) • MIR145 (MicroRNA 145)
    26d
    Diagnostic Challenges in the Pathological Approach to Pleural Mesothelioma. (PubMed, Cancers (Basel))
    In more challenging cases, molecular tests, such as fluorescent in situ hybridization (FISH) to detect CDKN2A deletion, can be helpful in distinguishing malignant from benign pleural lesions. This review summarizes the key morphological, immunohistochemical, and molecular features that should be considered when pleural biopsy samples are examined, with the aim of improving diagnostic accuracy in this complex area.
    Review • Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    CDKN2A deletion
    26d
    Prognostic Stratification of Epithelioid Pleural Mesothelioma Based on the Hippo-TEADs Network. (PubMed, Cancers (Basel))
    Higher levels of downstream Hippo effectors are associated with poor response to platinum-pemetrexed doublet and worse OS. The stratification of ePM based on the activation of the YAP/TAZ-TEAD axis is an intriguing approach in the light of the inhibitors of this signaling that are currently under investigation.
    Journal
    |
    YAP1 (Yes associated protein 1) • WWTR1 (WW Domain Containing Transcription Regulator 1) • VSIR (V-Set Immunoregulatory Receptor)
    |
    pemetrexed • Undisclosed YAP/TAZ-TEAD inhibitor
    26d
    A Multi-Center Real-World Study of Clinicopathologic Characteristics and Efficacy of the Malignant Mesothelioma in Chinese Population. (PubMed, Thorac Cancer)
    Chinese population with MM present unique clinicopathologic characteristics and could benefit from the first-line immunotherapy and bevacizumab combined with chemotherapy. Gender, histologic subtype, and CK5/6 are prognosis factors for OS. BAP1 deletions correlate with OS benefit.
    Journal • Real-world evidence • IO biomarker
    |
    BAP1 (BRCA1 Associated Protein 1)
    |
    Avastin (bevacizumab) • cisplatin • carboplatin
    26d
    A combination of PD-1 and TIGIT immune checkpoint inhibitors elicits a strong anti-tumour response in mesothelioma. (PubMed, J Exp Clin Cancer Res)
    These findings provide rationale for the development of an anti-PD-1 + TIGIT combination immunotherapy trial for mesothelioma patients.
    Journal • Checkpoint inhibition
    |
    PD-1 (Programmed cell death 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • pemetrexed
    26d
    Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project. (PubMed, JCO Precis Oncol)
    Although no prognostic value of CD276 expression was found, its high membranous expression (86%) in the PM samples of the study supports further research of its potential as a therapeutic target for this disease.
    Journal • IO biomarker
    |
    CD276 (CD276 Molecule)
    27d
    Treatment of Malignant Peritoneal Mesothelioma (MESOTIP) (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, Institut du Cancer de Montpellier - Val d'Aurelle | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cisplatin • doxorubicin hydrochloride • pemetrexed
    1m
    Pleural small cell carcinoma: A case report. (PubMed, Indian J Pathol Microbiol)
    The cells were negative for CK5/6, WT1, and mesothelin. A detailed morphological examination plays an important role in ruling out all the tumors displaying small cell features at this site, and a limited IHC panel can aid in arriving at a diagnosis of primary pleural SCC.
    Journal
    |
    MSLN (Mesothelin) • WT1 (WT1 Transcription Factor) • NKX2-1 (NK2 Homeobox 1) • SYP (Synaptophysin)
    1m
    BRCA1-Associated Protein-1 Inactivated Melanoma Arising in a Pre-existing Nevus With ALK Fusion and Low Tumor Mutational Burden. (PubMed, Am J Dermatopathol)
    The tumor was completely excised with negative margins. The patient is doing well at 17 months follow-up with no signs of recurrence.
    Journal • Tumor mutational burden • BRCA Biomarker
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • FGFR3 (Fibroblast growth factor receptor 3) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • BAP1 (BRCA1 Associated Protein 1) • VHL (von Hippel-Lindau tumor suppressor) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • PRAME (Preferentially Expressed Antigen In Melanoma) • MAP2K7 (Mitogen-Activated Protein Kinase Kinase 7) • RREB1 (Ras Responsive Element Binding Protein 1)
    |
    TP53 mutation • BRAF V600E • BRAF V600 • ALK positive • TMB-L • ALK fusion • ALK mutation
    1m
    SLC13A5 plays an essential role in the energy shift to oxidative phosphorylation in cisplatin-resistant mesothelioma stem cells. (PubMed, Pathol Int)
    Our findings suggest that the hydrogel-based CSC generation method is also effective for human mesothelioma cells and that SLC13A5 may contribute to MesoSC survival. The new properties of MesoSCs revealed in this study may provide clues for establishing future treatments.
    Journal
    |
    SOX2
    |
    cisplatin
    1m
    NICITA: Nivolumab with Chemotherapy in Pleural Mesothelioma After Surgery (clinicaltrials.gov)
    P2, N=92, Completed, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Active, not recruiting --> Completed
    Trial completion
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • pemetrexed
    1m
    ACROPOLI: Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors (clinicaltrials.gov)
    P2, N=184, Active, not recruiting, SOLTI Breast Cancer Research Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-1 (Programmed cell death 1)
    |
    Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001)
    1m
    TRuST: A Study to Assess the Long-term Safety of Tazemetostat (clinicaltrials.gov)
    P1/2, N=58, Active, not recruiting, Epizyme, Inc. | Enrolling by invitation --> Active, not recruiting | N=100 --> 58
    Enrollment closed • Enrollment change
    |
    Tazverik (tazemetostat)
    1m
    CK-301-101: Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers (clinicaltrials.gov)
    P1, N=272, Active, not recruiting, Checkpoint Therapeutics, Inc. | Recruiting --> Active, not recruiting | N=500 --> 272 | Trial completion date: Dec 2024 --> Dec 2025
    Enrollment closed • Enrollment change • Trial completion date
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Unloxcyt (cosibelimab-ipdl)
    1m
    BASECAMP-1: Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, A2 Biotherapeutics Inc. | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    1m
    Decoding the Molecular Enigma Behind Asbestos and Fibrous Nanomaterial-induced carcinogenesis. (PubMed, J Occup Health)
    Physical dimension, biopersistence and affinity to iron/histones are essential for fibrous material to be carcinogenic to mesothelial cells. Therefore, local iron reduction maybe a strategy to prevent mesothelial carcinogenesis.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    1m
    The Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter Analysis. (PubMed, Medicina (Kaunas))
    CAR is a strong independent prognostic factor in MPM, reflecting systemic inflammation and nutritional status. Epithelioid histology and early-stage disease are associated with significantly longer survival, underscoring the critical role of early detection in improving patient outcomes.
    Clinical • Retrospective data • Journal
    |
    CRP (C-reactive protein)
    1m
    Analysis of TERT mRNA Levels and Clinicopathological Features in Patients with Peritoneal Mesothelioma. (PubMed, Cancers (Basel))
    TERT is highly expressed in PeM, but it is not one of the crucial factors in evaluating the prognosis of patients. Nevertheless, the results validate the prognostic significance of the mitotic index, BAP1 loss and p16/CDKN2A status.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • MTAP (Methylthioadenosine Phosphorylase) • BAP1 (BRCA1 Associated Protein 1)